Xiong Dian, Wu Yong-Bing, Jin Chun, Li Ji-Jun, Gu Jie, Liao Yun-Fei, Long Xiang, Zhu Shu-Qiang, Wu Hai-Bo, Xu Jian-Jun, Ding Jian-Yong
Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China.
Department of Thoracic Surgery, The Affiliated Zhongshan Hospital of Fudan University, Shanghai 200032, P.R. China.
Oncol Lett. 2018 Aug;16(2):1791-1800. doi: 10.3892/ol.2018.8816. Epub 2018 May 25.
Fused in sarcoma/translocated in liposarcoma (FUS/TLS), a ubiquitous and multifunctional DNA and RNA-binding protein, contributes an important function in cancer and neurodegenerative disease; however, its role in lung cancer remains unclear. In the present study, the expression of FUS/TLS in non-small cell lung cancer (NSCLC) and the significance of FUS/TLS for predicting the clinical outcome of patients with NSCLC, was examined. FUS/TLS expression was investigated in NSCLC tissues and their matched adjacent non-tumorous tissues by reverse transcription-quantitative polymerase chain reaction, western blotting, and immunohistochemistry. Tissue microarrays representing 208 patients with NSCLC were used to determine the expression pattern and associations with FUS/TLS using immunohistochemistry. Prognostic significance was assessed by Kaplan-Meier survival estimates and log-rank tests. Data revealed that FUS/TLS expression was elevated in NSCLC tissues compared with corresponding normal tissue mRNA (9.27±0.73 vs. 6.15±0.60) and protein (3.32±0.75 vs. 0.30±0.07) levels. In tissue microarrays, FUS/TLS was highly expressed in 103 (49.5%, 103/208) NSCLC tissues compared with adjacent normal lung tissues (28.4%, 59/208). Overexpression of FUS/TLS was associated with higher tumor node metastasis stage (P=0.016), poorer differentiation (P=0.008), large tumor size (P=0.019) and predicted poor prognosis (P=0.005) in patients with NSCLC. Notably, correlation analysis revealed a significant inverse association between the expression of FUS/TLS and E-cadherin (r=0.51; P=0.036). Furthermore, patients with NSCLC with high FUS/TLS and impaired E-cadherin expression had a notably poor prognosis (P=4.01×10). Thus, the results from the present study indicate that elevated FUS/TLS expression promotes NSCLC progression. FUS/TLS, alone or in combination with E-cadherin, is a novel prognostic predictor for patients with NSCLC.
肉瘤融合蛋白/脂肪肉瘤易位蛋白（FUS/TLS）是一种广泛存在的多功能DNA和RNA结合蛋白，在癌症和神经退行性疾病中发挥重要作用；然而，其在肺癌中的作用尚不清楚。在本研究中，检测了FUS/TLS在非小细胞肺癌（NSCLC）中的表达及其对预测NSCLC患者临床结局的意义。通过逆转录定量聚合酶链反应、蛋白质印迹法和免疫组织化学法，研究了NSCLC组织及其配对的相邻非肿瘤组织中FUS/TLS的表达。使用代表208例NSCLC患者的组织芯片，通过免疫组织化学法确定FUS/TLS的表达模式及其相关性。通过Kaplan-Meier生存估计和对数秩检验评估预后意义。数据显示，与相应正常组织的mRNA（9.27±0.73对6.15±0.60）和蛋白质（3.32±0.75对0.30±0.07）水平相比，NSCLC组织中FUS/TLS表达升高。在组织芯片中，与相邻正常肺组织（28.4%，59/208）相比，103例（49.5%，103/208）NSCLC组织中FUS/TLS高表达。FUS/TLS过表达与NSCLC患者更高的肿瘤淋巴结转移分期（P=0.016）、更差的分化程度（P=0.008）、更大的肿瘤大小（P=0.019）相关，并预测预后不良（P=0.005）。值得注意的是，相关性分析显示FUS/TLS表达与E-钙黏蛋白之间存在显著负相关（r=0.51；P=0.036）。此外，FUS/TLS高表达且E-钙黏蛋白表达受损的NSCLC患者预后明显较差（P=4.01×10）。因此
